Associated Papers
Comprehensive Analysis of Human Colorectal Cancers Harboring Polymerase Epsilon Mutations.
Gibson LM et al.
International Journal of Molecular Sciences, 2025
40806338 (PubMed )
Supplement: ijms-26-07208-s001.zip › Table_S1.xlsx › S1A_COSMIC_mutation
Computational image and molecular analysis reveal unique prognostic features of immune architecture in African Versus European American women with endometrial cancer.
Azarianpour S et al.
Npj Precision Oncology, 2025
40550926 (PubMed )
Supplement: 41698_2025_972_MOESM2_ESM.xlsx › Supplementary_Data_S1
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Mur P et al.
Genome Medicine, 2023
37848928 (PubMed )
Supplement: 13073_2023_1234_MOESM6_ESM.xlsx › Table_S6
Tumor collagens predict genetic features and patient outcomes.
Guo KS et al.
Npj Genomic Medicine, 2023
37414817 (PubMed )
Supplement: 41525_2023_358_MOESM3_ESM.xlsx › UCEC
In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries.
Das Ghosh D et al.
Gynecologic Oncology Reports, 2023
37293351 (PubMed )
Supplement: mmc2.xlsx › MSI
Detection and characterization of constitutive replication origins defined by DNA polymerase epsilon.
Jaksik R et al.
Bmc Biology, 2023
36829160 (PubMed )
Supplement: 12915_2023_1527_MOESM1_ESM.xlsx › Tab1
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX et al.
Clinical and Translational Medicine, 2021
34586735 (PubMed )
Supplement: CTM2-11-e524-s001.xlsx › Supplementary_Table_2
Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
Fang H et al.
Plos Genetics, 2020
32012149 (PubMed )
Supplement: pgen.1008572.s015.xlsx › Supplementary_table_6
The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM et al.
Oncotarget, 2016
27612425 (PubMed )
Supplement: oncotarget-07-68638-s005.xlsx › Sheet1
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2015
DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN et al.
Human Molecular Genetics, 2013
23528559 (PubMed )
Supplement: supp_ddt131_ddt131supp.pdf
Select a paper to view details